{"data":{"id":"us/21-cfr-522.224","jurisdiction":"us","citation":"21 CFR 522.224","heading":"Bupivacaine.","body":"(a) Specifications. Each milliliter (mL) of liposomal suspension contains 13.3 milligrams (mg) bupivacaine.\n(b) Sponsor. See No. 058198 in § 510.600(c) of this chapter.\n(c) Conditions of use—(1) Dogs—(i) Amount. Administer 5.3 mg/kg (0.4 mL/kg) by infiltration injection into the tissue layers at the time of incisional closure.\n(ii) Indications for use. For single-dose infiltration into the surgical site to provide local postoperative analgesia for cranial cruciate ligament surgery.\n(2) Cats—(i) Amount. Administer 5.3 mg/kg per forelimb (0.4 mL/kg per forelimb), for a total dose of 10.6 mg/kg/cat, as a 4-point nerve block prior to onychectomy.\n(ii) Indications for use. For use as a peripheral nerve block to provide regional postoperative analgesia following onychectomy.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER E—ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS","PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"02900930e0912ec4c9d90b3ad8ec1375acf3287209b87cfb53bc3d96ba64239c","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-522.204","next":"us/21-cfr-522.230"},"notice":"GroundRules: Original legal text. Not legal advice."}